Fax: (713) 794-4999
Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract
Article first published online: 26 APR 2005
Copyright © 2005 American Cancer Society
Volume 103, Issue 11, pages 2355–2362, 1 June 2005
How to Cite
Giglio, P., Weinberg, J. S., Forman, A. D., Wolff, R. and Groves, M. D. (2005), Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer, 103: 2355–2362. doi: 10.1002/cncr.21082
- Issue published online: 18 MAY 2005
- Article first published online: 26 APR 2005
- Manuscript Accepted: 11 FEB 2005
- Manuscript Revised: 31 JAN 2005
- Manuscript Received: 20 MAY 2004
- Roche Pharmaceuticals
- Enzon Pharmaceuticals
- neoplastic meningitis;
- leptomeningeal carcinomatosis;
- gastrointestinal carcinoma
Neoplastic meningitis (NM) occurs in 5–10% of patients with malignant disease. Little is known about the outcomes of patients with gastrointestinal (GI) malignancies who develop NM. For this report, the authors characterized the clinical course and attempted to identify prognostic factors in patients with NM due to primary malignancies of the GI tract.
In this retrospective study, 21 patients with GI primary tumors and NM were identified: Their medical records and imaging studies were reviewed.
The patient population was composed of patients with gastric adenocarcinoma (n = 8 patients), esophageal adenocarcinoma (n = 7 patients), colon and/or rectal adenocarcinoma (n = 5 patients), and pancreatic adenocarcinoma (n = 1 patient). The median overall survival after the initial diagnosis of adenocarcinoma was 55 weeks (range, 8–884 wks), and the median survival after the diagnosis of NM was 7 weeks (range, 0–64 wks). Four patients died during palliative radiotherapy. No factors identified had an impact on outcome, including symptoms, physical findings at diagnosis, imaging characteristics, or cerebrospinal fluid findings. Univariate analysis showed a trend toward better outcomes for patients who received any kind of treatment directed toward the NM.
Patients with NM from GI tract adenocarcinomas universally had poor outcomes. Until NM can be diagnosed earlier and/or until more effective therapies are identified, comfort care alone may be a reasonable alternative for some of these unfortunate patients. Cancer 2005. © 2005 American Cancer Society.